May 21, 2024
Endocrine Therapy Drugs Market

The Endocrine Therapy Drugs (ETDS) Market  is driven by increasing prevalence of hormonal disorders

The endocrine therapy drugs are used for treating various hormonal disorders and cancers. These drugs help in stimulating or inhibiting the secretion of hormones and help regulate functions of endocrine glands. Some common endocrine therapy drugs include tamoxifen, aromatase inhibitors, GnRH agonists, etc. Tamoxifen is one of the widely used drug for treating breast cancer. Aromatase inhibitors such as anastrozole and letrozole play a key role in lowering estrogen levels in postmenopausal women. These drugs help in controlling growth and spread of cancer cells. The increasing prevalence of hormonal disorders such as breast cancer, prostate cancer, endometriosis and other hormonally sensitive cancers is driving the demand for endocrine therapy drugs globally.

The global Endocrine Therapy Drugs (ETDS) Market is estimated to be valued at US$ 35060.96 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the key trends in the Endocrine Therapy Drugs (ETDS) Market  is the increasing preference for targeted drugs over conventional drugs. Traditional chemotherapy drugs have severe side effects owing to their non-selective nature. Targeted endocrine therapy drugs selectively attack cancer cells while minimizing harm to healthy cells. Drugs such as aromatase inhibitors, selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs) demonstrate superior efficacy and improved safety profiles compared to traditional chemotherapy. This is encouraging research on development of newer targeted drugs with improved selectivity and more benefits over existing drugs.

Porter’s Analysis
Threat of new entrants: The threat of new entrants is low to moderate given the established brands and distribution networks of existing players. Significant investments are required to enter the market.
Bargaining power of buyers: The bargaining power of buyers is moderate given the availability of substitutes and presence of many established brands. Buyers can negotiate on pricing.
Bargaining power of suppliers: The bargaining power of suppliers is low to moderate as there are many suppliers for raw materials. Suppliers may raise prices if demand increases significantly.
Threat of new substitutes: Threat of new substitutes is moderate as there are alternative therapies available. However, switching costs for patients on existing therapies can limit substitution.
Competitive rivalry: Competition is fierce amongst existing players given their established brands, distribution reach and continuous new product launches.

Key Takeaways
The Global Endocrine Therapy Drugs (ETDS) Market Size is expected to witness high growth over the forecast period driven by increasing prevalence of hormone-sensitive cancers and rising awareness. The global Endocrine Therapy Drugs (ETDS) Market  is estimated to be valued at US$ 35060.96 Mn  in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.

Regional analysis: North America dominated the market in 2021 due to high healthcare spending and presence of many global brands. Asia Pacific is expected to witness fastest growth going forward supported by growing healthcare infrastructure and raising affordability in the region.

Key players operating in the Endocrine Therapy Drugs (ETDS) Market  are Johnson & Johnson, Procter & Gamble, Kimberly-Clark, Essity Aktiebolag (publ), Kao Corporation, Daio Paper Corporation, Unicharm Corporation, Premier FMCG, Ontex, Hengan International Group Company Ltd., Drylock Technologies, Natracare LLC, First Quality Enterprises Inc. and Bingbing Paper Co., Ltd.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it